First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 537 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas September 9, 2020 Frederick National Laboratory for Cancer Research: A Unique Resource for the... March 28, 2023 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α April 1, 2021 Load more HOT NEWS A recipe for hydration! pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... Twins Born 15 Minutes Apart Have Birthdays In Different Years Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer
